💊

Nilotinib Accord

nilotinib

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

✅ Authorised Generic

✅

No active alerts

This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Nilotinib Accord is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, - adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, - paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.

⚠️ Patient safety

Official EMA page

https://www.ema.europa.eu/en/medicines/human/EPAR/nilotinib-accord